Novartis and Biological E agree to deliver affordable vaccines for typhoid and paratyphoid A fevers to developing world

Novartis today announced that it has entered into a development and licensing agreement with Biological E Limited (BioE), a biopharmaceutical company based in India, for two vaccines to protect against typhoid and paratyphoid fevers. The agreement advances the Novartis goal to deliver accessible and affordable vaccines that address unmet medical need in endemic regions.

Continue reading. 

New York Times reports on price cuts for HPV vaccine

Thanks to Pap tests, fatal cervical cancers are almost unknown today in rich countries. But the disease kills an estimated 275,000 women a year in poor countries where Pap tests are impractical and the vaccine is far too expensive for the average woman to afford, so the price cut could lead to a significant advance in women’s health.

How purchasing power can help prevent child deaths: lessons for Asia from the Americas

In an article published today on Reuters, Sabin Executive Vice President Dr. Ciro de Quadros and Tony Nelson of the ROTA Council describe how actions taken by Latin American countries to protect children from rotavirus, the leading cause of diarhea hospitalizations and deaths, could be used in other regions of the world severely impacted by this killer disease of children.

Pages